Mor Moskovitz - Concepedia

Author

Mor Moskovitz

Rambam Health Care Campus

Also Known As

J. Bar, M Moskovitz, M. MOSKOVITZ, M. Moskovitz, Mor Moskovitz, Mor T. Moskovitz, Mor Tal Moskovitz, Sara Moore

121

Publications

1.9K

Citations

H-Index

Concepts

All Affiliations

Rambam Health Care Campus Rabin Medical Center Sheba Medical Center Tel Aviv University Princess Margaret Cancer Centre

About

Mor Moskovitz is an author at Rambam Health Care Campus specializing in medicine, cancer therapeutics, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	769
2	Health Sciences	5	5	292
3	Gastroenterology	2	2	66
4	Hepatology	2	2	56
5	Emergency Medicine	1	1	45

Mor Moskovitz

Publications

1.7K

Citations

H-Index

Page 1

	Year	Citations
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors Elizabeth Dudnik, Nir Peled, Hovav Nechushtan, Journal of Thoracic Oncology Tumor Mutational BurdenDeath Ligand 1MedicineImmunologyCancer Genomics	2018	219
Cannabis Consumption Used by Cancer Patients during Immunotherapy Correlates with Poor Clinical Outcome Gil Bar‐Sela, Idan Cohen, Salvatore Campisi‐Pinto, Cancers Poor Clinical OutcomeCancer ManagementImmunologyImmunoeditingCancer Patients	2020	124
Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, <i>EGFR</i> –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer James Chih‐Hsin Yang, Dae Ho Lee, Jong‐Seok Lee, Journal of Clinical Oncology	2024	123
Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial Benjamin Besse, Elvire Pons‐Tostivint, Keunchil Park, Nature Medicine	2024	102
Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life data Elizabeth Dudnik, Mor Moskovitz, Sameh Daher, Lung Cancer Real-life DataMedicineCancer ManagementImmune Checkpoint InhibitorCancer Treatment	2017	101
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein–Overexpressing Advanced Nonsquamous <i>EGFR</i> -Wildtype Non–Small Cell Lung Cancer in the Phase II LUMINOSITY Trial D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Journal of Clinical Oncology	2024	99
ALK-Rearranged Non–Small-Cell Lung Cancer Is Associated With a High Rate of Venous Thromboembolism Alona Zer, Mor Moskovitz, David Hwang, Clinical Lung Cancer	2016	98
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study Natasha B. Leighl, Hiroaki Akamatsu, Sun Min Lim, Journal of Clinical Oncology	2024	94
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN) Jair Bar, Nir Peled, Shiruyeh Schokrpur, Journal of Thoracic Oncology	2022	92
Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC). D. Ross Camidge, Jair Bar, Hidehito Horinouchi, Journal of Clinical Oncology Telisotuzumab VedotinC-met AntibodyMedicineAntibody-drug ConjugateMetronomic Therapy	2022	70

Page 1